Skip to main content

Table 4 Concordance of Patient Recall with Medical Chart Data in Reporting Use of the 10 Most Commonly Prescribed Chemotherapeutic Agents for Breast Cancer Treatment, Shanghai, China, 2002-2006.

From: Concordance of self-reported and medical chart information on cancer diagnosis and treatment

Chemotherapeutic Agent % that reported use of drug on PQa % of MCb that reported use of drug Agreement (%) Kappa
Fluorouracil 71.0 68.8 84.9 0.64
Cyclophosphamide 70.1 59.7 82.5 0.62
Epirubicin 52.4 46.0 81.7 0.64
Methotrexate 19.6 16.1 92.1 0.73
Calcium folinate 14.7 14.4 85.4 0.41
Pirarubicin 12.4 8.8 90.8 0.51
Novel drugs c 9.5 4.7 95.7 0.63
Vinorelbine 8.1 6.9 96.7 0.76
Docetaxel 4.2 2.4 97.8 0.65
Paclitaxel 3.4 2.5 98.0 0.65
  1. a PQ: Patient questionnaire.
  2. b MC: Medical chart.
  3. c Novel drugs include the following list of pharmaceuticals, all of which were approved in China for use in breast cancer patients in 2002, the year both surveys were conducted: altretamine, oxaliplatin, gemcitabine, trastuzumab, ifosfamide, temozolomide, and Aredia.